| 000 | 01319 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250515150926.0 | ||
| 264 | 0 | _c20090107 | |
| 008 | 200901s 0 0 eng d | ||
| 022 | _a1532-1924 | ||
| 024 | 7 |
_a10.1016/j.beha.2008.07.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFerrara, James L M | |
| 245 | 0 | 0 |
_aAdvances in the clinical management of GVHD. _h[electronic resource] |
| 260 |
_bBest practice & research. Clinical haematology _cDec 2008 |
||
| 300 |
_a677-82 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 | _aDisease Management |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xdiagnosis |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHepatocyte Growth Factor |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 | _aInterleukin-8 |
| 650 | 0 | 4 | _aReceptors, Interleukin-2 |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 | _aReceptors, Tumor Necrosis Factor, Type I |
| 650 | 0 | 4 |
_aSteroids _xtherapeutic use |
| 773 | 0 |
_tBest practice & research. Clinical haematology _gvol. 21 _gno. 4 _gp. 677-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.beha.2008.07.003 _zAvailable from publisher's website |
| 999 |
_c18496966 _d18496966 |
||